Related Experiment Video

Updated: Aug 18, 2026

A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model
06:02

A Contemporary Warming/Restraining Device for Efficient Tail Vein Injections in a Murine Fungal Sepsis Model

Published on: November 6, 2020

[Therapy of intraabdominal fungal infections]

P Kujath1, R Bouchard, J Nolde

  • 1Klinik für Chirurgie, Universitätsklinikum Schleswig-Holstein, D-23538 Lübeck, Germany. kujath-luebeck@t-online.de

Mycoses
|April 14, 2005
PubMed

Insights

Candida albicans is a common surgical intensive care unit pathogen. A new four-stage classification helps differentiate contamination from invasive candidiasis, guiding antifungal therapy decisions.

Area of Science:

  • Medical Microbiology
  • Infectious Diseases
  • Critical Care Medicine

Background:

  • Candida albicans is the fourth most common microorganism found in surgical intensive care units (SICUs).
  • Accurate interpretation of Candida-positive samples is challenging for physicians managing severe peritonitis.
  • Distinguishing between contamination and invasive fungal infections is critical due to associated high mortality rates.

Purpose of the Study:

  • To propose a novel four-stage classification system for Candida-related infections in the abdominal cavity.
  • To aid in differentiating between harmless contamination and invasive candidiasis.
  • To provide clear guidelines for the initiation of antimycotic therapy.

Main Methods:

  • Development of a four-stage classification system based on the presence and extent of Candida.
  • Stage I: Initial contamination.
  • Stages IIa/IIb: Fungal persistence with/without risk factors.
  • Stage III: Histological evidence of invasion.
  • Stage IV: Generalized infection (fungemia/fungal sepsis).

Main Results:

  • The proposed classification categorizes Candida infections from initial contamination to generalized sepsis.
  • Stage IIb and higher indicate a need for intervention.
  • This framework facilitates clinical decision-making regarding antifungal treatment.

Conclusions:

  • A four-stage classification system can effectively guide the management of Candida infections in SICU patients with peritonitis.
  • Antimycotic therapy is recommended for patients classified as Stage IIb or higher.
  • This approach aims to improve patient outcomes by ensuring timely and appropriate treatment for invasive fungal infections.

Related Concept Videos

Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Fungal Phylum Microsporidia01:28

Fungal Phylum Microsporidia

Microsporidia are a group of obligate intracellular fungi that were initially classified as protists but were later reclassified based on phylogenetic, molecular, and structural evidence linking them to the Chytridiomycota. These unicellular, non-motile organisms are highly specialized parasites that infect a wide range of animal hosts, including humans. They have evolved extensive genomic and metabolic reductions, making them highly dependent on their hosts for survival.Morphology and Genomic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...